UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer

Annals of oncology, 2008-06, Vol.19 (6), p.1068-1074

2008

Volltextzugriff (PDF)

Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age

Clinical pharmacology and therapeutics, 2011-11, Vol.90 (5), p.693-700

2011

Volltextzugriff (PDF)

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Journal of clinical oncology, 1997-06, Vol.15 (6), p.2403-2413

1997

Volltextzugriff (PDF)

Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer

The pharmacogenomics journal, 2017-12, Vol.17 (6), p.521-527

2017

Volltextzugriff (PDF)

CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment

JNCI : Journal of the National Cancer Institute, 2005-01, Vol.97 (1), p.30-39

2005

Volltextzugriff (PDF)

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

Annals of oncology, 1996-04, Vol.7 (4), p.347-353

1996

Volltextzugriff (PDF)

Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients

The pharmacogenomics journal, 2009-08, Vol.9 (4), p.258-264

2009

Volltextzugriff (PDF)

Factors underlying metastatic breast cancer patients' perceptions of symptom importance: a qualitative analysis

European journal of cancer care, 2018-01, Vol.27 (1), p.e12540-n/a

2018

Volltextzugriff (PDF)

Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects

British journal of cancer, 2013-10, Vol.109 (9), p.2331-2339

2013

Volltextzugriff (PDF)

Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study

British journal of cancer, 2010-07, Vol.103 (3), p.291-296

2010

Volltextzugriff (PDF)

An Investigational new drug treatment program for patients with gemcitabine : Results for over 3000 patients with pancreatic carcinoma

Cancer, 1999-03, Vol.85 (6), p.1261-1268

1999

Volltextzugriff (PDF)

Assessing clinical benefit in the treatment of pancreas cancer: Gemcitabine compared to 5-fluorouracil

European journal of cancer (1990), 1997, Vol.33, p.S18-S22

1997

Volltextzugriff (PDF)

Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy

British journal of cancer, 2010-01, Vol.102 (2), p.294-300

2010

Volltextzugriff (PDF)

A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy

Cancer, 1999-05, Vol.85 (9), p.2023-2032

1999

Volltextzugriff (PDF)

A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin

Clinical cancer research, 1997-04, Vol.3 (4), p.537-543

1997

Volltextzugriff (PDF)

Rapid superselective high-dose cisplatin infusion for advanced head and neck malignancies

Head & neck, 1992-09, Vol.14 (5), p.364-371

1992

Volltextzugriff (PDF)

Modeling hot flushes and quality of life in breast cancer survivors

Climacteric : the journal of the International Menopause Society, 2011-02, Vol.14 (1), p.171-180

2011

Volltextzugriff (PDF)

Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer

Journal of clinical oncology, 1994-10, Vol.12 (10), p.2113-2120

1994

Volltextzugriff (PDF)

Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy

Journal of clinical oncology, 1992-03, Vol.10 (3), p.464-473

1992

Volltextzugriff (PDF)

Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial

Journal of clinical oncology, 2023-12, Vol.41 (36), p.5482-5492

2023

Volltextzugriff (PDF)

Chronic myelomonocytic leukemia

Leukemia, 1990-11, Vol.4 (11), p.766-770

1990

Volltextzugriff (PDF)

Preclinical, pharmacologic, and phase I studies of gemcitabine

Seminars in oncology, 1997-04, Vol.24 (2 Suppl 7), p.S7

1997

Volltextzugriff (PDF)

Phase 1 study of bispecific HER2 antibody-drug conjugate MEDI4276 in patients with advanced HER2-positive breast or gastric cancer

Annals of oncology, 2018-03, Vol.29, p.iii8-iii8

2018

Volltextzugriff (PDF)

47OPhase 1 study of bispecific HER2 antibody-drug conjugate MEDI4276 in patients with advanced HER2-positive breast or gastric cancer

Annals of oncology, 2018-03, Vol.29 (suppl_3)

2018

Volltextzugriff (PDF)

Recombinant Human Erythropoietin Therapy for Anemic Cancer Patients on Combination Chemotherapy

JNCI : Journal of the National Cancer Institute, 1993-05, Vol.85 (10), p.801-806

1993

Volltextzugriff (PDF)

1 – 25 von 227

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(219)
Mit Volltextzugriff
(206)

Publikationsform

Sprache

Englisch
(227)
Japanisch
(15)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer

Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer

CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients

Factors underlying metastatic breast cancer patients' perceptions of symptom importance: a qualitative analysis

Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects

Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study

An Investigational new drug treatment program for patients with gemcitabine : Results for over 3000 patients with pancreatic carcinoma

Assessing clinical benefit in the treatment of pancreas cancer: Gemcitabine compared to 5-fluorouracil

Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy

A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy

A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin

Rapid superselective high-dose cisplatin infusion for advanced head and neck malignancies

Modeling hot flushes and quality of life in breast cancer survivors

Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer

Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy

Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial

Chronic myelomonocytic leukemia

Preclinical, pharmacologic, and phase I studies of gemcitabine

Phase 1 study of bispecific HER2 antibody-drug conjugate MEDI4276 in patients with advanced HER2-positive breast or gastric cancer

47OPhase 1 study of bispecific HER2 antibody-drug conjugate MEDI4276 in patients with advanced HER2-positive breast or gastric cancer

Recombinant Human Erythropoietin Therapy for Anemic Cancer Patients on Combination Chemotherapy

Suchergebnisse filtern